Literature DB >> 24682140

Central pontine myelinolysis: electrolytes and beyond.

J V Mascarenhas1, E B Jude.   

Abstract

Central pontine myelinolysis (CPM), which is a component of the osmotic demyelination syndrome (ODS), is a frequent neurological complication that follows rapid correction of hyponatraemia. However, there are other predisposing risk factors (chronic alcoholism, hypokalaemia) that perpetuate the development of ODS. We report a case of a 39-year-old woman with a history of chronic alcoholism who presented to us with progressive neurological deficits (paraparesis, paresthesias). She was initially detected to have coexisting hypokalaemia which was eventually rectified with potassium supplementation. However, she continued to experience progressive worsening of her neurological symptoms despite adequate potassium supplementation. Therefore, a neurological opinion was sought for and she was diagnosed with CPM based on a background of chronic alcoholism and malnutrition; an MRI of the brain showed a hyperintense signal in the central pontine region. Following the diagnosis of CPM, she was rehabilitated with occupational and physiotherapy.

Entities:  

Mesh:

Year:  2014        PMID: 24682140      PMCID: PMC3975522          DOI: 10.1136/bcr-2013-203516

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  15 in total

1.  Outcome of central pontine and extrapontine myelinolysis (n = 44).

Authors:  H Menger; J Jörg
Journal:  J Neurol       Date:  1999-08       Impact factor: 4.849

2.  Mechanisms of hyponatraemia in alcohol patients.

Authors:  G L Liamis; H J Milionis; E C Rizos; K C Siamopoulos; M S Elisaf
Journal:  Alcohol Alcohol       Date:  2000 Nov-Dec       Impact factor: 2.826

Review 3.  A review of the causes of central pontine myelinosis: yet another apoptotic illness?

Authors:  H Ashrafian; P Davey
Journal:  Eur J Neurol       Date:  2001-03       Impact factor: 6.089

Review 4.  Central pontine and extrapontine myelinolysis: the osmotic demyelination syndromes.

Authors:  R J Martin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-09       Impact factor: 10.154

Review 5.  The management of symptomatic hyponatremia.

Authors:  R H Sterns
Journal:  Semin Nephrol       Date:  1990-11       Impact factor: 5.299

Review 6.  Treating hyponatremia: damned if we do and damned if we don't.

Authors:  T Berl
Journal:  Kidney Int       Date:  1990-03       Impact factor: 10.612

Review 7.  Myelinolysis after correction of hyponatremia.

Authors:  R Laureno; B I Karp
Journal:  Ann Intern Med       Date:  1997-01-01       Impact factor: 25.391

8.  Pontine and extrapontine myelinolysis.

Authors:  D G Wright; R Laureno; M Victor
Journal:  Brain       Date:  1979-06       Impact factor: 13.501

Review 9.  Central pontine and extrapontine myelinolysis: a report of 58 cases.

Authors:  A Gocht; H J Colmant
Journal:  Clin Neuropathol       Date:  1987 Nov-Dec       Impact factor: 1.368

Review 10.  Osmotic demyelination syndrome following correction of hyponatremia: association with hypokalemia.

Authors:  J W Lohr
Journal:  Am J Med       Date:  1994-05       Impact factor: 4.965

View more
  3 in total

Review 1.  Brain-behavior relations and effects of aging and common comorbidities in alcohol use disorder: A review.

Authors:  Edith V Sullivan; Adolf Pfefferbaum
Journal:  Neuropsychology       Date:  2019-09       Impact factor: 3.295

Review 2.  Magnesium, Calcium, Potassium, Sodium, Phosphorus, Selenium, Zinc, and Chromium Levels in Alcohol Use Disorder: A Review.

Authors:  Jacek Baj; Wojciech Flieger; Grzegorz Teresiński; Grzegorz Buszewicz; Ryszard Sitarz; Alicja Forma; Kaja Karakuła; Ryszard Maciejewski
Journal:  J Clin Med       Date:  2020-06-18       Impact factor: 4.241

3.  Apathetic encephalopathy in thyreotoxicosis: an unsual cause of wernicke encephalopathy and osmotic demyelinating syndrome.

Authors:  Carlotta Mutti; Rosario Ciliento; Liborio Parrino; Irene Florindo; Giovanni Pavesi; Lucia Zinno
Journal:  Acta Biomed       Date:  2021-02-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.